GastroenteroloGy

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy for patients, who might be as young as 2 years of age.

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.

Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.

Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients' response to infliximab and adalimumab.

Identification of early-onset IBD patients may enable tailored treatment and surveillance plans. With over 50 genes implicated in early-onset IBD, genetic testing should be included in the workup of children under the age of six with IBD. Join Mayo Clinic, in this “Specialty Testing” webinar, for a discussion of this testing and its clinical application.

The MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor evaluates for somatic mutations in solid tumor samples and determines microsatellite instability to confirm a diagnosis of GIST.

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.

Mayo Clinic researchers and collaborators have discovered a critical role that inflammation plays in liver regeneration after liver resection. While effective regeneration requires some inflammation, too much of it causes regeneration failure. They also discovered that patients experiencing dysfunctional liver regeneration had a significantly dysregulated gene known as DUSP4 – a finding that could help support targeted therapeutic strategies administered before or after surgical resection to prevent liver failure.

In this "Hot Topic," Melissa Snyder, Ph.D., provides a brief review of published guidelines for the diagnosis of celiac disease, with a specific focus on the role of laboratory testing.

A new serum test for bile acid malabsorption. Descriptions illustrate how the test can be used as a screening test and as a tool for therapeutic action.

Mayo Clinic researchers are now using artificial intelligence (AI) systems to help increase polyp detection during colonoscopies and identify colorectal cancer at an early stage. Like facial recognition software that recognizes faces, this AI tool is being trained to recognize polyps. It works alongside the physician during a colonoscopy, scanning the video feed and drawing boxes around polyps that may otherwise have been overlooked due to their subtleness.

As someone affected by chronic liver disease, Susan Parrott knows how it feels to live in uncertainty. But every few months, the anxiety and doubt that shadow her life fade when Mayo Clinic Laboratories test results confirm her condition is in check and she can continue living life on her own terms.